neo-gambogic acid profile

neo-gambogic acid: from Gamboge (Garcinia hanburryi); structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6438568
MeSH ID	M0133152

Synonym
neo-gambogic acid
2-butenoic acid, 4-(3a,4,5,7,10,11-hexahydro-8,9-dihydroxy-3,3,11-trimethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1h,3h,9h-furo(3,4-g)pyrano(3,2-b)xanthen-1-yl)-2-methyl-
(e)-4-[10,12-dihydroxy-8,21,21-trimethyl-5-(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.02,15.02,19.04,13.06,11]docosa-4(13),5,11,15-tetraen-19-yl]-2-methylbut-2-enoic acid
AKOS040758796
FS-6930
1428127-36-9
4-(8,9-dihydroxy-2,2,11-trimethyl-13-(3-methylbut-2-en-1-yl)-11-(4-methylpent-3-en-1-yl)-4,7-dioxo-1,2,5,7,10,11-hexahydro-9h-1,5-methanofuro[3,2-g]pyrano[3,2-b]xanthen-3a(4h)-yl)-2-methylbut-2-enoic acid

Excerpt	Reference	Relevance
" This validated method was successfully applied to a pharmacokinetic study after intravenous injection administration of gambogenic acid in dogs at a dose of 1 mg/kg."	( Ultra-high-performance liquid chromatography tandem mass spectrometry method for the determination of gambogenic acid in dog plasma and its application to a pharmacokinetic study. Chen, JP; Wang, CY; Wang, DL; Wang, SS; Yang, LL, 2014)	0.4
" The pharmacokinetic parameters of the two agents were compared."	( Preparation of Neogambogic Acid Nanoliposomes and its Pharmacokinetics in Rats. Cong, JZ; Hou, JF; Li, XM; Liu, JW; Liu, SJ; Tong, L; Zhang, Y, 2018)	0.48
" The pharmacokinetics results in rats showed that GNA-NLC plasma concentration was significantly higher than that of common preparation of gambogic acid, with a half-life period of 10."	( Preparation of Neogambogic Acid Nanoliposomes and its Pharmacokinetics in Rats. Cong, JZ; Hou, JF; Li, XM; Liu, JW; Liu, SJ; Tong, L; Zhang, Y, 2018)	0.48
" However, short biological half-life and low oral bioavailability severely limit its clinical application."	( Preparation and preliminary pharmacokinetics study of GNA-loaded zein nanoparticles. Chen, W; Cheng, W; Dong, Q; Hong, L; Qian, J; Wang, B; Zha, L; Zhang, C, 2019)	0.51
" The in vitro release profile, in vivo pharmacokinetic experiments and tissue distribution of GNA-ZN-NPs were also evaluated."	( Preparation and preliminary pharmacokinetics study of GNA-loaded zein nanoparticles. Chen, W; Cheng, W; Dong, Q; Hong, L; Qian, J; Wang, B; Zha, L; Zhang, C, 2019)	0.51
"GNA-ZN-NPs significantly enhanced the oral bioavailability and prolonged half-life of GNA, providing a promising oral drug delivery system to improve in vivo pharmacokinetic behaviour of GNA."	( Preparation and preliminary pharmacokinetics study of GNA-loaded zein nanoparticles. Chen, W; Cheng, W; Dong, Q; Hong, L; Qian, J; Wang, B; Zha, L; Zhang, C, 2019)	0.51

Excerpt	Reference	Relevance
" However, short biological half-life and low oral bioavailability severely limit its clinical application."	( Preparation and preliminary pharmacokinetics study of GNA-loaded zein nanoparticles. Chen, W; Cheng, W; Dong, Q; Hong, L; Qian, J; Wang, B; Zha, L; Zhang, C, 2019)	0.51
"GNA-ZN-NPs significantly enhanced the oral bioavailability and prolonged half-life of GNA, providing a promising oral drug delivery system to improve in vivo pharmacokinetic behaviour of GNA."	( Preparation and preliminary pharmacokinetics study of GNA-loaded zein nanoparticles. Chen, W; Cheng, W; Dong, Q; Hong, L; Qian, J; Wang, B; Zha, L; Zhang, C, 2019)	0.51

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (1.61)	18.7374
1990's	1 (1.61)	18.2507
2000's	0 (0.00)	29.6817
2010's	42 (67.74)	24.3611
2020's	18 (29.03)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (1.59%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	62 (98.41%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
bupropion Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.	2.17	1	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.31	1	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
chlorzoxazone Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.	2.17	1	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.1	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	2.17	1	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	6.62	59	xanthene
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.6	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
cerium Cerium: An element of the rare earth family of metals. It has the atomic symbol Ce, atomic number 58, and atomic weight 140.12. Cerium is a malleable metal used in industrial applications.	2.11	1	f-block element atom; lanthanoid atom
4-phenylbutylamine 4-phenylbutylamine: used as a drug partition into lipid bilayers in a cubic liquid-crystalline phase. 4-phenylbutylamine : A phenylalkylamine that is benzene in which one of the hydrogens is substituted by a 4-aminobutyl group.	2.6	1	benzenes; phenylalkylamine; primary amino compound
sb 203580 [no description available]	2.06	1	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
erlotinib hydrochloride [no description available]	2.17	1	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
rhodamine 123 Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.	2.21	1	organic cation; xanthene dye	fluorochrome
1-monooleoyl-rac-glycerol Peceol: lipid excipient containing readily dispersible mixture of mono- & diglycerides of oleic acid. 1-oleoylglycerol : A 1-monoglyceride where the acyl group is oleoyl.. monooleoylglycerol : A monoglyceride in which the acyl group is oleoyl with the position of acylation unspecified.	2.11	1	1-acylglycerol 18:1; monooleoylglycerol	plant metabolite
gambogic acid gambogic acid: RN given refers to (1R-(1alpha,1(Z),3abeta,5alpha,11beta,14aS*))-isomer	2.58	2	pyranoxanthones	metabolite
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.47	2
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.47	2
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	3.14	4	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient

Condition	Relationship Strength	Studies
Hepatocellular Carcinoma [description not available]	2.83	3
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.83	3
Colorectal Cancer [description not available]	7.72	2
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.72	2
Cirrhosis [description not available]	2.41	1
Ureteral Obstruction Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.	2.41	1
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.41	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	2.41	1
Malignant Melanoma [description not available]	3.16	4
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	3.16	4
Cancer of Prostate [description not available]	2.6	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.6	1
Benign Neoplasms [description not available]	3.6	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.6	2
Osteogenic Sarcoma [description not available]	2.76	2
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	7.76	2
Cancer of Skin [description not available]	2.76	2
Skin Neoplasms Tumors or cancer of the SKIN.	2.76	2
Carcinoma, Non-Small Cell Lung [description not available]	2.61	2
Cancer of Lung [description not available]	3.62	8
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.61	2
Lung Neoplasms Tumors or cancer of the LUNG.	3.62	8
Bladder Cancer [description not available]	2.25	1
Metastase [description not available]	2.25	1
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.25	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.25	1
Cicatrix, Hypertrophic An elevated scar, resembling a KELOID, but which does not spread into surrounding tissues. It is formed by enlargement and overgrowth of cicatricial tissue and regresses spontaneously.	2.31	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.89	3
Injuries Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.	2.31	1
Wounds and Injuries Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.	2.31	1
Acute Liver Injury, Drug-Induced [description not available]	2.31	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.31	1
Cancer of Cervix [description not available]	2.13	1
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.13	1
Cancer of Liver [description not available]	2.81	3
Liver Neoplasms Tumors or cancer of the LIVER.	2.81	3
Angiogenesis, Pathologic [description not available]	2.52	2
Carcinoma, Small Cell Lung [description not available]	2.21	1
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	2.21	1
Breast Cancer [description not available]	8.01	4
Breast Neoplasms Tumors or cancer of the human BREAST.	3.01	4
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.1	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.1	1
Cancer of Stomach [description not available]	2.1	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.1	1
B16 Melanoma [description not available]	2.1	1
Innate Inflammatory Response [description not available]	2.13	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.13	1
Alveolitis, Fibrosing [description not available]	2.13	1
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	2.13	1
Adenocarcinoma, Basal Cell [description not available]	2.05	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.05	1
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	2.06	1
Carcinoma, Anaplastic [description not available]	2.06	1
Cancer of Nasopharynx [description not available]	2.06	1
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.06	1
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	2.06	1
Benign Neoplasms, Brain [description not available]	2.07	1
Astrocytoma, Grade IV [description not available]	2.07	1
Invasiveness, Neoplasm [description not available]	2.07	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.07	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.07	1

neo-gambogic acid

Description

Cross-References

Synonyms (7)

Research Excerpts

Pharmacokinetics

Bioavailability

Research

Studies (62)

Study Types

neo-gambogic acid

Description

Cross-References

Synonyms (7)

Research Excerpts

Pharmacokinetics

Bioavailability

Research

Studies (62)

Study Types

Related Drugs (17)

Related Conditions (62)